drugset / Trial / NCT00890968

Safety and Efficacy Study of Triamcinolone Acetonide DuraPeel to Treat Hand Dermatitis

NCT00890968

Phase 2 Completed 56 enrolled ZARS Pharma Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether Triamcinolone Acetonide (TAC) DuraPeel is safe and effective in the treatment of hand dermatitis.

Timeline

Start
2009-04
Primary completion
2009-06
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Triamcinolone Acetonide Other / unclassified 0.5 % Topical

Indications